FRT2 Antibody

What is FLRT2 and what are the fundamental applications of FLRT2 antibodies in research?

FLRT2 (fibronectin leucine-rich repeat transmembrane) is one of three FLRT glycoproteins expressed in distinct areas of the developing brain and other tissues . These proteins play important roles in cell adhesion, neurodevelopment, and cell signaling pathways.

FLRT2 antibodies are primarily used for:

• Detection of FLRT2 expression in various cell types and tissues

• Western blot analysis (detecting bands at approximately 80 kDa under reducing conditions)

• Simple Western™ analysis (detecting bands at approximately 139 kDa)

• Immunohistochemistry to study FLRT2 distribution in tissues

• Studying protein-protein interactions involving FLRT2

The antibody specifically recognizes the region from Cys36-Ser539 of human FLRT2 (Accession # O43155) . Most commercially available antibodies are optimized for specific applications, so researchers should validate each antibody for their particular experimental conditions.

How can I validate the specificity of FLRT2 antibodies for my experimental applications?

Antibody specificity is crucial for reliable research outcomes. Several methodological approaches can help validate FLRT2 antibody specificity:

Western Blot Validation Protocol:

• Run positive controls (e.g., NCI-H460 human large cell lung carcinoma cell line lysates) alongside experimental samples

• Include negative controls (cell lines known not to express FLRT2)

• Observe specific bands at approximately 80 kDa under reducing conditions using Western Blot Buffer Group 1

• Verify that the observed molecular weight matches the expected size for FLRT2

Advanced Validation Techniques:

• Use FLRT2 knockout/knockdown cells as negative controls

• Perform peptide competition assays using the specific epitope recognized by the antibody

• Conduct cross-reactivity tests with other FLRT family members (FLRT1, FLRT3)

• Implement high-throughput specificity profiling methods similar to those described for other antibodies

Specificity assessment is particularly important as antibodies may exhibit binding to structurally similar proteins, which could result in false positive results or misinterpretation of experimental data.

What are the optimal experimental conditions for using FLRT2 antibodies in Western blot applications?

Based on documented protocols, the following methodology has proven effective for FLRT2 detection by Western blot:

Recommended Protocol:

• Prepare cell lysates in appropriate lysis buffer (preferably containing protease inhibitors)

• Separate proteins using SDS-PAGE under reducing conditions

• Transfer proteins to PVDF membrane

• Block membrane with appropriate blocking buffer

• Probe with FLRT2 antibody at 1 μg/ml concentration

• Use HRP-conjugated Anti-Goat IgG Secondary Antibody (for goat primary antibodies)

• Develop using enhanced chemiluminescence detection system

Critical Parameters:

• PVDF membranes typically yield better results than nitrocellulose for FLRT2 detection

• Reducing conditions are essential for accurate size determination

• Buffer systems significantly impact band resolution (Western Blot Buffer Group 1 recommended)

• Optimal antibody dilution should be determined empirically for each lot

This methodology has been validated using NCI-H460 human large cell lung carcinoma cell line, which can serve as a positive control for FLRT2 expression .

How can I apply high-throughput methods for mapping FLRT2 antibody specificity and cross-reactivity?

Recent advances in antibody characterization have introduced sophisticated high-throughput methods for mapping protein-protein interactions that can be applied to FLRT2 antibodies:

PolyMap Methodology Adaptation:

• Establish a robust FLRT2 surface display platform using mammalian expression systems

• Generate stable cell lines expressing FLRT2 variants (consider both lentiviral transduction and Flp-recombinase-mediated integration)

• Include specific mutations in the FLRT2 sequence to map epitope recognition

• Use cytomegalovirus (CMV) promoter with translation-enhancing sequence elements

• Implement unique barcode identification for each FLRT2 variant

• Analyze antibody binding using flow cytometry

• Process data using computational analysis to identify distinct binding modes

This approach can provide detailed mapping of epitope recognition and help identify potential cross-reactivity with other proteins. The methodology allows researchers to test multiple antibody clones against numerous FLRT2 variants simultaneously.

For optimal expression, consider using CHOZN cells with FRT integration sites, which have demonstrated 3.5-fold higher surface expression compared to Expi293 cells for other membrane proteins .

What methodological considerations should I make when designing experiments to avoid false positives with FLRT2 antibodies?

False positive results represent a significant challenge in antibody-based research. Several methodological approaches can minimize this risk:

Critical Controls and Considerations:

• Employ multiple detection methods to confirm FLRT2 identification

• Include genetic validation through knockdown/knockout approaches

• Use competing peptides to confirm epitope specificity

• Implement careful antibody titration to determine optimal concentrations

Addressing Common Sources of False Positives:

• Non-specific binding: Optimize blocking conditions (typically 5% BSA or milk in TBST)

• Cross-reactivity: Test against purified FLRT1 and FLRT3 proteins

• Batch variation: Maintain detailed records of antibody lot numbers and validation data

• Sample preparation artifacts: Standardize lysis conditions and protein extraction methods

Modern computational approaches can also help predict potential cross-reactivity. Recent research has demonstrated the design of antibodies with customized specificity profiles using computational models trained on phage display data . Similar approaches could be adapted for FLRT2 antibody specificity assessment.

How does complement activation affect antibody-based detection systems for targets like FLRT2?

Complement activation can significantly influence antibody-based detection systems through various mechanisms that researchers should consider:

Impact on Detection Systems:

• Complement components may create background signals in immunoassays

• C1q binding to antibodies can affect epitope accessibility

• Complement receptor interactions may influence antibody trafficking in cell-based assays

Methodological Considerations:

• Heat-inactivate serum components in culture media

• Consider using complement inhibitors when necessary

• Be aware that complement activation via the classical pathway (initiated by C1q) leads to generation of C3 split products and ligation of CR1/CR2

• The impairment of antibody responses in Cr2 KO mice resembles those found in mice lacking C1q, C4, or C3, implying a linear relationship in complement activation

For FLRT2 detection in tissues with high complement activity, researchers may need to implement specialized protocols to minimize interference from complement components.

What are the key methodological approaches for phenotypic screening using antibodies that can be applied to FLRT2 research?

Phenotypic screening represents a powerful approach for identifying antibodies with specific functional properties. These methods can be adapted for FLRT2 research:

Methodological Framework:

• Target-agnostic screening using phage display libraries against cells expressing FLRT2

• Selection of binding molecules with desired properties (e.g., agonistic or antagonistic activity)

• Functional validation through cell-based assays

• Characterization of binding kinetics and epitope mapping

This approach has been successfully implemented for other targets, such as TNFR2, where novel agonist antibodies were identified through phenotypic screening . The methodology allowed researchers to discover antibodies that could activate specific signaling pathways.

For FLRT2 research, similar approaches could identify antibodies that modulate FLRT2-dependent cellular processes, potentially leading to new insights into its biological functions and therapeutic applications.

How can I design experiments to determine if post-translational modifications affect FLRT2 antibody recognition?

Post-translational modifications (PTMs) can significantly impact antibody recognition. The following methodological approach can help characterize these effects:

Experimental Design:

• Generate recombinant FLRT2 with and without specific PTMs

• Compare antibody binding through ELISA, Western blot, and flow cytometry

• Use enzymatic treatments to remove specific modifications:

  • PNGase F for N-linked glycosylation

  • O-glycosidase for O-linked glycosylation

  • Phosphatases for phosphorylation

• Analyze binding affinities before and after treatment

Important Considerations:

• FLRT2 is a glycoprotein with potential glycosylation sites

• Different cell lines may produce FLRT2 with varying glycosylation patterns

• The native 80 kDa band detected in Western blot vs. the 139 kDa band in Simple Western™ may reflect different glycosylation states

• Expression systems can impact PTM patterns (mammalian systems typically provide more native-like glycosylation)

This methodological approach will help researchers select antibodies appropriate for their specific application, particularly when studying FLRT2 in different cellular contexts.

What are the best practices for developing and validating custom FLRT2 antibodies for specialized research applications?

Developing custom antibodies requires rigorous methodology to ensure specificity and functionality:

Development Protocol:

• Select appropriate immunogen (consider both full-length FLRT2 and specific peptide regions)

• Choose optimal host species based on research needs

• Implement screening strategies to identify high-affinity binders

• Purify antibodies using antigen-specific affinity chromatography

Validation Methodology:

• Determine binding kinetics using surface plasmon resonance (SPR)

• Assess epitope specificity through peptide arrays or hydrogen-deuterium exchange mass spectrometry

• Evaluate cross-reactivity against related proteins (FLRT1, FLRT3)

• Validate functionality in multiple assay formats

Advanced Approaches:

Recent research demonstrates computational design of antibodies with customized specificity profiles using models trained on phage display data . This approach involves:

• Identifying different binding modes associated with particular ligands

• Using computational models to design new antibody sequences with desired specificity

• Experimentally validating designed antibodies

• Iteratively refining the model based on experimental results

This computational methodology could be applied to design FLRT2 antibodies with specific binding properties for specialized research applications.

How can I effectively troubleshoot inconsistent results when using FLRT2 antibodies in different experimental systems?

Inconsistent results represent a common challenge in antibody-based research. The following methodological framework can help systematically address variability:

Troubleshooting Protocol:

• Document all experimental variables:

  • Antibody lot number and storage conditions

  • Sample preparation method

  • Blocking reagents and buffers

  • Incubation times and temperatures

  • Detection systems

• Perform systematic optimization:

  • Titrate antibody concentration (typically starting at 1 μg/ml for FLRT2 antibodies)

  • Test multiple blocking reagents (BSA, milk, commercial blockers)

  • Optimize incubation times and temperatures

  • Evaluate different detection systems

• Control for cellular expression systems:

  • CHOZN cells with FRT integration sites have demonstrated 3.5-fold higher surface expression compared to Expi293 cells for membrane proteins

  • Consider CMV promoter with translation-enhancing sequence elements for optimal expression

• Address epitope accessibility issues:

  • Try different sample preparation methods (native vs. denatured)

  • Consider epitope retrieval techniques for fixed samples

  • Test multiple antibody clones recognizing different epitopes

By systematically addressing these variables, researchers can identify and resolve sources of inconsistency in FLRT2 antibody experiments, leading to more reproducible and reliable results.